It is reported that "Jianjia robot" has recently completed a round C financing of hundreds of millions of yuan. The current round of financing was led by lyfe capital, followed by Softbank China capital, and the old shareholders Hillhouse venture capital and Fosun Pharmaceutical continued to raise. The financing amount was nearly 400 million yuan within one year. The raised funds will be used to promote the clinical trial of knee replacement surgical robots and the R & D and clinical registration of new products such as other surgical robots.
"Jianjia robot", established in 2018, is a platform enterprise of hard tissue surgical robot. The hip replacement robot, the company's fastest-growing product, has completed clinical enrollment and follow-up. At the same time, it is also the first "total hip replacement robot" product to enter the special review procedure of nmpa innovative medical devices in China. It is expected to become the first approved domestic joint replacement robot. In addition, the company has a number of new products such as surgical robots in the R & D and inspection stage.
Dr. Xu Jing, founder of "Jianjia robot", believes that the success of traditional joint replacement surgery depends very much on the experience and skills of doctors. In the future, the application of joint surgery robot will become the only breakthrough to improve the accuracy of prosthesis implantation and help the volume of joint replacement surgery. Clinical data show that the hip robot of Jianjia can control the final operation error within 1mm and the installation angle deviation within 1 °, which significantly improves the problems of poor unarmed operation accuracy, long learning curve and perennial intraoperative radiation exposure in previous hip arthroplasty. In addition, in terms of preoperative planning, registration and calibration, Kejia robot has also been optimized to additionally support femoral side processing, and can be compatible with prostheses from different manufacturers as an open platform.
In addition, the company has a number of new products such as surgical robots in the R & D and inspection stage, among which the knee robot will carry out formal clinical trials in the near future.
Jiang Min, partner of Softbank China capital, said: surgical robots have obvious clinical advantages in improving surgical accuracy and controlling complications, reducing the threshold of surgical learning and shortening the training cycle of doctors, and have become the key development technology of surgery. At present, there is a huge gap in the penetration rate of joint replacement between China and the United States, and the development prospect of domestic joint replacement market is good.
Liu Yi, vice president of Fosun medicine and chairman of medical device division, said: the accelerated aging has brought about an increasing demand for joint replacement surgery year by year. The development goal of joint replacement surgery in recent years is to improve the surgical accuracy, shorten the recovery time of patients and allow joint replacement surgery to be carried out in more hospitals. Surgical robot provides an effective solution to improve the accuracy and consistency of joint replacement surgery.
36 krypton noticed that there are Fuhua medical, tianzhihang, Stryker, intuitive surgery and other companies in the orthopaedic surgery robot track; In the field of orthopaedic implants, related companies include Aikang medical and Shandong Weigao.
